Effects that we observe emanate from allelic heterozygosity, but because GRP78-inhibiting compounds have been generated, more forceful therapeutic reduction of GRP78 activity and thereby stronger anti-tumor effects may be feasible without overt toxicities. The gene discussed is HSPA5; the disease is neoplasm.